PSMA specific antibodies and their diagnostic and therapeutic use

Expert Opinion on Investigational Drugs

Volumn 10, Issue 3, 2001, Pages 511-519

  Holmes, E H ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

Antibody therapy; Linear sequence epitopes; Monoclonal antibodies; Prostate cancer; Prostate specific membrane antigen; Protein conformational epitopes; PSMA

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMINO ACID; ANTISERUM; BIOCHEMICAL MARKER; BISMUTH 213; CANCER ANTIBODY; CAPROMAB PENDETIDE IN 111; CELL SURFACE PROTEIN; CONTRAST MEDIUM; CYTOTOXIC AGENT; EPITOPE; GLYCOPROTEIN; HLA A2 ANTIGEN; IMMUNOGLOBULIN M; IODINE 131; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAYTANSINE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F5.4G6; MONOCLONAL ANTIBODY 7E11.C5; PEPTIDE ANTIBODY; PEPTIDE DERIVATIVE; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; CANCER CELL; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENDOCRINE DISEASE; EPITHELIUM CELL; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; IN VIVO STUDY; MEMBRANE BINDING; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DOMAIN; REVIEW; SEQUENCE ANALYSIS; UROGENITAL SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0035117123     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.3.511     Document Type: Review

References (56)

1. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
2. Analysis of glycosylation of prostate specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors and serum from prostate cancer patients
3. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
4. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization
5. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids
6. Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody 7E11-C5
7. In vitro and in vivo reactivity of anti-prostate monoclonal antibody immunoconjugate 7E11.C5.3-GYK-DTPA. Antibody Immunoconj
8. Prostate-specific membrane antigen expression in normal and malignant human tissues
9. Upregulation of prostate-specific antigen after androgen deprivation therapy
10. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine
11. Expression of the prostate-specific membrane antigen
12. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues
13. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: Study of 184 cases
14. Prostate specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
15. Five different anti-prostate-specific specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
16. Prostate-specific membrane antigen is produced in tumor-associated neovasculature
17. Biochemical characterization and mapping of the 7e11-C5.3 epitope of the prostate-specific membrane antigen
18. Prediction of protein antigenic determinants from amino acid sequences
19. Measurement of prostate-specific membrane antigen in the serum with a new antibody
20. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response
21. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
22. Constitutive and antibody-induced internalization of prostate-specific membrane antigen
23. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
24. ext)
25. 90Y-huJ591 Mab specific to PSMA: Radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor
26. 213Bi]J591) for radioimmunotherapy of prostate cancer
27. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
28. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA)
29. Xenogeneic genetic immunization with prostate-specific membrane antigen cDNAs
30. Development of human monoclonal antibodies specific for extracellular epitopes in prostate-specific membrane antigen (PSMA)
31. Lymph node involvement in prostatic carcinoma
32. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy
33. Prostate cancer imaging with a new monoclonal antibody: A preliminary report
34. Radioscintiscanning of prostate cancer
35. Indium-111 capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
36. 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence
37. 111Indium-labeled monoclonal antibody CYT-356
38. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: Positron emission tomography and biopsy correlation
39. Indium-111 capromab monoclonal antibody: Utility in differentiating local versus distant relapse after radical prostatectomy
40. Monoclonal antibody imaging of recurrent and metastatic prostate cancer
41. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
42. Comparison of staging algorithms and a monoclonal antibody scan (ProstaScint) to predict lymph node involvement in high-risk prostate cancer
43. Imaging prostate cancer with technetium-99m-7E11.C5.3 (CYT-351)
44. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide
45. ProstaScint may enhance identification of prostate cancer recurrence after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients
46. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
47. Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint scanning in prostatic cancer patients
48. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer
49. Evaluation of PSA, free PSA, PSMA and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer
50. 90Y-CYT-356 monoclonal antibody
51. A novel humanised antibody against prostate-specific membrane antigen (PSMA) for in vivo targeting and therapy
52. ext) in patients with hormone-independent prostate cancer
53. Monoclonal antibody therapy for prostate cancer
54. UICC workshop on the use of dendritic cells in cancer clinical trials
55. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment